Laura Magazzini

The productivity crisis in pharmaceutical R&D

Advances in the understanding of the molecular basis of diseases have expanded the number of plausible therapeutic targets for the development of innovative agents in recent decades. However, although investment in pharmaceutical research and development (R&D) has increased substantially in this time, the lack of a corresponding increase in the output in terms of new drugs being approved indicates that therapeutic innovation has become more challenging. Here, using a large database that contains information on R&D projects for more than 28,000 compounds investigated since 1990, we examine the decline of R&D productivity in pharmaceuticals in the past two decades and its determinants. We show that this decline is associated with an increasing concentration of R&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms. We also investigate the potential variations in productivity with regard to the regional location of companies and find that although companies based in the United States and Europe differ in the composition of their R&D portfolios, there is no evidence of any productivity gap.

Learning from failures or failing to learn? Lessons from pharmaceutical R&D

Innovation is a trial and error process in which both successes and failures contribute to knowledge creation and destruction. In this paper we test theoretical predictions about the role of failures in new product development on private and public knowledge and interfirm knowledge transfer. We analyse the outcomes of world‐wide R&D projects in the pharmaceutical industry, and proxy knowledge flows with forward citations received by patents associated with each project. We find that patents covering successfully completed projects (i.e., leading to drug launch on the market) receive more citations than those associated to failed (terminated) projects, which in turn are cited more often than patents lacking clinical or preclinical information. Failures by specialized firms are cited more frequently than the ones of generalist companies. We therefore offer evidence of the value of failures as research inputs in (pharmaceutical) innovation.

Patent disclosure and R&D competition in pharmaceuticals

The prominent role played by patents within the pharmaceutical domain is unquestionable. In this paper, we focus on a relatively neglected implication of patents: the effect of patent-induced information disclosure on the dynamics of R&D and market competition. The study builds upon the combination of two large datasets, linking the information about patents to firm-level data on R&D projects and their outcome. Two case studies in the fields of anti-inflammatory compounds and cancer research complement our analysis. We argue that patent disclosure induces R&D competition and shapes firms’ technological trajectories. In fact, we show that under conditions of uncertainty, patent disclosure can contribute to generate knowledge spillovers, promoting multiple parallel research efforts on plausible targets and stimulating private investment and competition.

Resale Price Maintenance: An Empirical Analysis of UK Firms' Compliance

Empirical evidence on resale price maintenance (RPM) is scarce. This article provides novel empirical evidence based on a unique database of RPM complaints, lodged in the UK to the Office of Fair Trading (OFT) between 2007 and 2009. We describe the characteristics of the commodity being traded and of the relevant upstream and downstream firms and their sectors. We then present an econometric analysis to assess how the probability of compliance to the OFT request to withdraw the RPM can be affected by the specific features of the relevant economic context in which this restraint has taken place.

Does Regulation drive International Research Cooperation? Evidence from the Pharmaceutical Sector

To what extent is an increased stringency of the Intellectual Property Rights (IPR) system apt to stimulate research cooperation between developed and emerging economies? To address this question, we empirically investigate how international joint research projects in the pharmaceutical sector are affected by the regime of IPR in force in the two countries involved in the collaboration. Looking at the joint signature of both patent documents and scientific papers by researchers located in developed and emerging markets, our investigation indicates two opposite effects: joint publications are fostered by stricter IPR rules, whereas joint patents are discouraged. A recently proposed theory provides a plausible rationale for this apparently contradicting result.